VLP Production Platform — R&D Workflow
How a modular 4-protein virus-like-particle candidate is screened end to end: design & cloning, dual-vector rescue and amplification, titration, co-infection & self-assembly, clarification, and QC. Only the antigen changes between the 100+ constructs — everything downstream is a fixed pipeline.
- Stages
- 0–6
- Variable
- the antigen
- Make-or-break
- assembly
Primer
What is a virus-like particle?
A virus-like particle is a virus with the dangerous part removed. Its structural proteins self-assemble into the same shell geometry a real virus wears — but there is no genome inside. Nothing to replicate, nothing to integrate into a host chromosome, nothing to revert to a virulent form. To a B-cell it looks like an incoming pathogen; to the patient it is inert protein.
That geometry is the whole point. The immune system evolved to react hard to dense, repetitive surfaces — a real virion presents dozens to hundreds of identical spikes in a rigid lattice, which cross-links B-cell receptors and trips the complement cascade far more efficiently than a lone protein drifting past. A VLP copies that lattice, so it raises high neutralizing-antibody titers at a low dose, often without a heavy adjuvant.
VLPs sit between the two older vaccine styles. Live-attenuated virus is potent but carries a real genome and real risk; a soluble subunit protein is safe but weakly immunogenic. A VLP keeps most of the potency of the first with the safety of the second — which is why the Hepatitis B and HPV vaccines given to hundreds of millions of people are, structurally, VLPs.
What is new is treating the shell as a reusable platform: a fixed, validated backbone that carries a swappable antigen. That is exactly the logic this map traces — only the antigen changes across the 100+ constructs, and the entire downstream process is one pipeline. Build the process once; screen candidates for years.
- Design the antigen–backbone fusion in silico (linker, dual promoters polh / p10).
- Synthesise / assemble the fused gene cassettes.
- Clone the cassettes into transfer Plasmid A (genes 1 & 2) and Plasmid B (genes 3 & 4).
- Transform E. coli, pick clones, miniprep and sequence-verify (Sanger / NGS).
- Co-transfect host-cell monolayers in static multi-well plates: Plasmid A + linearised viral DNA in one set of wells, Plasmid B + viral DNA in another (never mixed).
- Homologous recombination inside the cells packages each plasmid's genes into recombinant Baculovirus Vector A / Vector B.
- Harvest un-amplified P0 seed per well (~100–200 µL) — separate stocks for Vector A and Vector B.
- Inoculate host-cell suspension in shaking bottles / T-flasks with P0 seed — a SEPARATE culture for Vector A and for Vector B (kept apart).
- Maintain continuous agitation (orbital shaking / rocking) to maximise aeration and viability.
- Perform daily manual or automated sampling to measure cell viability.
- Harvest at ~60% live/dead ratio. Execute an optional P2 passage if larger volumes are needed.
- Prepare serial dilutions of Vector A and Vector B working stocks across micro-plates.
- Inoculate reporter cells and incubate.
- Measure signal intensity across dilution steps to calculate infectious viral titers (PFU/mL).
- Co-infect host-cell suspension in large vessels (shake flasks up to 3 L) with Vectors A & B at the calibrated MOI.
- Incubate under continuous shaking / rocking.
- Draw daily samples to track host-cell mortality.
- Terminate culture at the target viability drop — signalling maximum VLP expression and secretion.
- Centrifuge the bulk harvest to pellet dead insect cells and heavy debris.
- Collect the VLP-containing supernatant and discard the cell pellet.
- Process the supernatant through TFF cassettes to concentrate VLPs and remove low-MW contaminants.
- Run SDS-PAGE and Western blotting to confirm presence and weights of all 4 structural proteins.
- Prepare negative-stain TEM grids and inspect particle size and spherical structure.
- Test antigen-binding affinity by SPR or ELISA.
- Perform safety and endotoxin screening prior to in-vivo mouse immunogenicity studies.

The molecular-biology team designs the antigen fusion and clones it into the two transfer plasmids — this is the ONE step that changes between experiments; everything after it is a fixed pipeline.

Co-transfect the two plasmids SEPARATELY (one set of wells each) to rescue recombinant baculovirus Vectors A and B — kept apart from the very start.

Propagate Vector A and Vector B in TWO separate cultures (never mixed) to build high-titer working stocks — they are only combined later, at Stage 4 co-infection.

Quantify infectious titers of A and B to set an exact 1:1 co-infection ratio — equal delivery of all 4 components.

Co-infect with A & B; ribosomes translate all 4 fused proteins concurrently, which self-assemble into antigen-displaying 3D VLPs.

Separate assembled VLPs from cells and debris — centrifuge out the cell pellet, then concentrate by TFF.

Confirm all 4 proteins are present in ratio and correctly assembled into intact, antigen-displaying particles.

Molecular biologist clones + sequence-verifies Plasmids A & B at the DNA bench.

Operator co-transfects 6-well plates inside the BSC · 2–3 hrs active.

Operator seeds shake bottles into the shaker + daily viability checks.

Operator lays out serial dilutions + reads the fluorometer plate.

Operator co-infects 3 L flasks + samples daily · 3–4 hrs active.

Operator runs the floor centrifuge, then TFF concentration.

Operator runs gels/blots, prepares TEM grids, reads SPR.
Thermocycler (PCR)Thermal cycler — runs the PCR / assembly reactions and colony-PCR checks during cloning.
DNA sequencerDNA sequencer — Sanger / NGS confirmation that each plasmid carries the correct fused insert.
Multichannel pipetteMultichannel pipette — parallel liquid handling across plate rows (dilutions, transfers, plating).
Conical tubes15/50 mL conical tubes — collect and store P0 seed supernatant, media and reagents.
Consumables: Transfer-plasmid backbones A & B · synthetic antigen DNA · assembly / restriction mix · competent E. coli · miniprep + sequencing kits
BSC Class IIClass II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
Static incubatorStatic CO₂ incubator — holds sealed culture plates at controlled temperature/CO₂ through the multi-day static rescue.
6-well (M6) plates6-well (M6) static plates — the vessel for co-transfecting host-cell monolayers at screening scale.
Conical tubes15/50 mL conical tubes — collect and store P0 seed supernatant, media and reagents.
Multichannel pipetteMultichannel pipette — parallel liquid handling across plate rows (dilutions, transfers, plating).
Consumables: M6 / M24 static plates · 15/50 mL conical tubes · sterile filter units · pipette tips
Shaker / rocker incubatorOrbital shaker / rocker incubator — continuous agitation to aerate suspension cultures and keep cells viable.
BSC Class IIClass II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
Automated cell counterAutomated cell counter — reads live/dead viability (Trypan Blue) from a microfluidic slide.
Microfluidic counting slideMicrofluidic counting slide — single-use cassette that feeds one sample to the cell counter.
Small shaking bottlesSmall shaking bottle — vented vessel for amplifying viral stocks in agitated suspension.
Consumables: Shaking bottles / T-flasks · Microfluidic counting slides · Trypan Blue reagent · Sampling vials · pipette tips
Microplate fluorometerMicroplate fluorometer / reader — measures reporter-cell fluorescence to compute infectious titer.
BSC Class IIClass II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
Multichannel pipetteMultichannel pipette — parallel liquid handling across plate rows (dilutions, transfers, plating).
Deep-well dilution platesDeep-well dilution plate — holds the serial-dilution series for titration.
Consumables: 96-well microplates · deep-well dilution plates · micropipette tips · optical plate seals
Large shaking incubatorOrbital shaker / rocker incubator — continuous agitation to aerate suspension cultures and keep cells viable.
BSC Class IIClass II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
Automated cell counterAutomated cell counter — reads live/dead viability (Trypan Blue) from a microfluidic slide.
1–3 L shake flasks1–3 L shake flask — the largest screening vessel, for the co-infection / VLP-assembly run.
Consumables: 1–3 L shake flasks / bottles · sampling syringes / vials · microfluidic counting slides · Trypan Blue reagent
High-capacity floor centrifugeHigh-capacity floor centrifuge — pellets dead cells and heavy debris from the bulk harvest.
TFF filtration skid + cassettesTFF filtration skid — tangential-flow cassettes concentrate the VLPs and wash out low-MW contaminants.
Peristaltic pumpPeristaltic pump — drives harvest/buffer through the TFF cassettes at a controlled, contamination-free flow.
Collection bottlesCollection bottle — sterile vessel for the clarified, concentrated VLP solution.
Consumables: Centrifuge bottles (500 mL–1 L) · TFF cassettes (100–300 kDa MWCO) · sanitary silicone tubing · collection bottles
Low-voltage TEM (Cryo-EM)Low-voltage TEM (Cryo-EM) — direct imaging of particle size and spherical structure (20–200 nm).
SDS-PAGE tankSDS-PAGE gel tank — separates the 4 structural proteins by molecular weight.
Western blot apparatusWestern blot transfer apparatus — transfers separated proteins to membrane for antibody detection.
Imaging systemGel / blot imaging system — captures chemiluminescent band images for QC records.
SPR / ELISA readerSPR / ELISA reader — measures the antigen-binding affinity of the displayed surface antigens.
Consumables: Polyacrylamide gels · PVDF membranes · carbon-coated TEM grids · chemiluminescent substrates · micro-tubes · filter paper
Illustrations generated in the A4BEE graphics style from labelled objects; every capability and step traces to the process definition. A modular 4-protein VLP structural backbone presents target antigens (e.g. HER2, GD2 mimetics, multi-epitope chains). Antigens are genetically fused onto backbone DNA — the cell synthesises pre-fused chimeric proteins that self-assemble; it never builds an empty shell. Four structural genes are split across two recombinant baculovirus vectors — Vector A (Backbone Proteins 1 & 2), Vector B (Backbone Proteins 3 & 4). Screening-scale throughput (96-/24-well → 6-well → shaking bottles → 3 L flasks); no industrial bioreactors at this stage.
Why this platform
What VLPs beat, and how
Beats soluble subunits on immunogenicity
A lone protein has no repetitive structure, so it needs high doses and strong adjuvants to protect. The VLP's multivalent geometry cross-links B-cell receptors and activates complement like a real virion — higher neutralizing titers, longer-lived immunity and stronger memory-B recall, at a lower antigen dose.
Safer than live-attenuated and viral vectors
No viral genome means no reversion to virulence, no genomic integration and no infectious risk — and it stays usable in immunocompromised patients. Unlike adenoviral vectors, there is no anti-vector immunity to blunt the boost on repeat dosing.
Ships without an ultra-cold chain
mRNA-LNP prototypes fast but lives at −80 to −20 °C. VLPs are physically and thermally sturdier — frequently stable at 2–8 °C, and lyophilizable toward ambient. That is the difference between reaching a clinic in a capital city and reaching one that isn't.
One backbone, many antigens
Insert a foreign epitope into a surface loop (chimeric and mosaic particles) or bolt it on with SpyTag/SpyCatcher, and a generic shell becomes a display platform. Viral, bacterial, parasitic, toxin and oncology targets attach to the same pre-manufactured backbone — platform flexibility with one standardized downstream process. This is the "only the antigen changes" thesis of the map.
History
Forty years of VLP vaccines
- 1986The first VLP vaccine — and the first recombinant vaccine
Hepatitis B surface antigen, expressed in yeast, self-assembles into empty particles (Recombivax HB, Engerix-B). The proof that a genome-free protein shell can protect at population scale.
- 2006Gardasil, then Cervarix — VLPs against cancer
HPV L1 capsid proteins assembled into VLPs become the first vaccines to prevent a human cancer, and the proof the platform scales to a global product.
- 2011Hecolin — the only Hepatitis E vaccine
Xiamen Innovax produces a Hep E VLP in E. coli — still the world's only licensed vaccine for the disease, and a demonstration that VLPs do not need mammalian or insect cells.
- 2012SpyTag / SpyCatcher — protein superglue
The Howarth lab in Oxford engineers a peptide-protein pair that forms a spontaneous covalent bond, letting an antigen snap onto a pre-made backbone. The technical basis for modern plug-and-display.
- 2021RTS,S / Mosquirix — the first malaria vaccine
WHO recommends a scaffold VLP that hangs a P. falciparum antigen on the Hep B surface protein — a chimeric particle carrying a target its backbone never came from.
- 2023–24Designed particles get hot; economics still bite
AstraZeneca acquires Icosavax and its computationally-designed two-component VLPs (RSV + hMPV) for over $1B, while Medicago's plant-made COVID VLP is approved and then wound down — the science is compelling, the manufacturing economics are not automatic.
Landscape
Who is building in this space
Merck
PharmaGardasil 9 (HPV) and Recombivax HB (Hep B) — the highest-volume proof that VLP vaccines manufacture and sell at global scale.
GSK
PharmaEngerix-B, Cervarix (HPV) and Mosquirix/RTS,S — the scaffold-VLP malaria vaccine that carries a parasite antigen on the Hep B surface protein.
Novavax
BiotechRecombinant protein-nanoparticle vaccines (COVID, flu) paired with its Matrix-M adjuvant — nanoparticle-adjacent rather than a classic VLP, but the same display-on-a-particle playbook.
SpyBiotech
Platform · Oxford spinoutCommercialising SpyTag/SpyCatcher plug-and-display; CMV and malaria candidates built on a snap-on backbone.
Vaxican
Startup · PolandA Polish startup developing virus-like-particle vaccines — an emerging European entrant building on the VLP-display approach.
Icosavax (AstraZeneca)
BiotechComputationally-designed two-component self-assembling VLPs; the RSV + hMPV combo (IVX-A12) drove a >$1B acquisition in 2024.
VBI Vaccines
BiotechEnveloped VLPs (eVLP) that add a lipid membrane for membrane-bound antigens; PreHevbrio (3-antigen Hep B) and a CMV programme.
Xiamen Innovax / Wantai
Pharma · ChinaHecolin — the only Hepatitis E vaccine anywhere — plus Cecolin (HPV), both E. coli-produced VLPs.
Serum Institute of India
PharmaCervavac, a low-cost HPV VLP engineered for high-volume, low-margin markets.
Medicago
Biotech · wound down 2023Plant-made VLPs; Covifenz was the first plant-produced COVID vaccine approved (Canada) before the programme closed — a reminder that platform novelty doesn't guarantee economics.
A4BEE's own research, compiled from public information. Company and product names are trademarks of their respective owners and are used here for identification only; this map is not affiliated with or endorsed by any of them.
What's inside
- A plain-language primer on what a VLP is and why the immune system reacts to it
- 7 stages (0–6) as columns — Design & Cloning through Structural QC — with two illustrated hero rows each (biology + operator process)
- Numbered process steps, the key bottleneck per stage, a labelled+described hardware row, and time & effort
- Why VLPs beat soluble subunits, live-attenuated virus, viral vectors and mRNA — and where they don't
- A 40-year history of VLP vaccines and a map of the companies and startups building in the space
Best used for
- Onboarding a team to a screening-scale VLP platform
- Reviewing where the throughput bottlenecks and scientific make-or-break points are
- Explaining the dual-vector logic (separate A & B until co-infection) to stakeholders
Questions about this resource?
Want it in a different format, need the methodology behind a number, or wondering how it applies to your programme? Ask a practitioner — a straight answer, usually within one business day.